The content on this website is intended for healthcare professionals and is not intented to be professional medical advice. The Instructions for Use (IFU) for the product must therefore be consulted before use of any product. Please be aware that the product and/or an indication might not be approved in your country, e.g. US. Please contact your Bentley representative for further information.

Close
January 5, 2023

From left to right: Rainer Bregulla (Director R & D), Sebastian Büchert (CEO), Thomas Morawek (Arnold Schwarzenegger Impersonator), Hartmut Grathwohl (Director Operations), Andrew Brabner (Director Finance & IT),  Christian Bader (Director Quality & Market Access)

Bentley launches the BeBack crossing catheter

Hechingen, January 2023 – Bentley, a global leader in the endovascular treatment for aortic and peripheral vascular disease, announces the launch of the BeBack crossing catheter designed for the treatment of heavily calcified lesions.

With the acquisition of the GoBack catheter in September 2022, Bentley marks a milestone in its young existence. Launched by Upstream Peripheral Technologies (Caesarea, Israel) in 2019, the device was available in 23 countries. Since the acquisition, the company managed to “re-brand” GoBack to BeBack, making sure that the device can benefit from the corporate branding and product synergies. It is Bentley’s intention to extend the global availability by its partner network to those countries that the company is already active in with its current product portfolio.

“Steering through Chronic Total Occlusions (CTO) is often the most challenging part when treating heavily calcified lesions,” said Martijn Nugteren – Director Sales & Marketing. “With the BeBack crossing catheter the physician has a great tool in hand to access and cross lesions to save limbs and reduce the number of amputations, thanks to the unique benefits of the device”.

The BeBack crossing catheter is available in an 80 and 120 cm catheter in both a 2.9 F and 4 F size. The device makes use of a steerable and in length adjustable Nitinol needle, which can be used for crossing and targeted re-entry purposes. A radiopaque marker indicates the direction in which the curved needle protrudes from the tip of the catheter. Multiple treatment options like antegrade, retrograde and crossover are possible with the BeBack crossing catheter for intraluminal and subintimal approaches of stenotic or occluded lesions.

The BeBack is CE marked and FDA cleared for commercial purposes.

 

Contact: Matthias Bleesen, Communication & Event Coordinator, m.bleesen@bentley.global, +49 7471 984 995 631

International

Customer service:
+49 7471 984 995 10

Contact

Bentley InnoMed GmbH

Lotzenäcker 3
72379 Hechingen / Germany
+49 7471 99 99-0

info@bentley.global

www.bentley.global

United States

Customer service:
+1 770 295 2288

Contact

Bentley US Inc.

2220 Northmont Pkwy. Suite 250
Duluth, GA 30096 / USA
+1 770 295 2288

info@bentley.global

www.bentley.global